Eye tests under the microscope for blinding disease
NCT ID NCT03845218
First seen Jun 26, 2026 · Last updated Sep 18, 2026 · Updated 6 times
Summary
This completed study looked at how well different eye tests can track changes in retinitis pigmentosa (RP), a group of blinding eye diseases. Researchers tested 49 people with RP and healthy volunteers using exams like vision tests, retinal imaging, and electrical signal recordings. The goal was to find which tests are most reliable for measuring disease progression, which could help design better future treatment trials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help design better clinical trials for retinitis pigmentosa treatments by identifying the most reliable tests.
- What could go wrong
- This was a small, observational study with no treatment tested. Results may not apply to all RP patients or lead directly to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
49 people
The number who actually took part.
- Started
-
Sep 2019
- Finished
-
Jul 2023
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Up to 120 participants aged 12 or older with a diagnosis of RP. Up to 30 healthy volunteers.@@@@@@
- Ages
-
12 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA for RP Participants: To be eligible, the following inclusion criteria must be met, where applicable. * Participant must be 12 years of age or older. * Participant (or legal guardian) must understand and sign the protocol s informed consent document. * Participant must have evidence of RP as defined by characteristic ERG responses, visual fields, clinical exam and /or genetic testing. INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS: To be eligible, the following inclusion criteria must be met: 1. Participant must be 18 years of age or older. 2. Participant must understand and sign the protocol s informed consent document. 3. Participant must not have evidence of RP. EXCLUSION CRITERIA FOR ALL PARTICIPANTS: A participant is not eligible if any of the following exclusion criteria are present. * Participant is actively receiving study therapy in another investigational study. * Participant is started on (or changed dosage of) topical or systemic carbonic anhydrase inhibitor (CAI) treatment in the three months prior to enrollment. * Participant is expected to be unable to comply with study procedures or follow-up visits. * Participant has evidence of an ocular disease other than RP in either eye that may confound the outcome of the study (e.g., diabetic retinopathy with ten or more hemorrhages or microaneurysms, uveitis, pseudovitelliform macular degeneration, severe myopia). * Participant is taking ocular or systemic medications known to be toxic to the lens, retina or optic nerve (e.g., ethambutol, chloroquine, or hydroxychloroquine). * Participant has a condition that would preclude participation in the study (e.g., unstable medical status including blood pressure and glycemic control) by interfering with the participant s ability to engage in the required protocol evaluation and testing and/or comply with study visits. * Participant is an NIH employee associated with this study. * Participant is unable or unwilling to give informed consent that includes use of medical records and clinical samples for current and future research.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Retinitis pigmentosa are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single eye injection restore sight in genetic blindness?
- A sharper look at the retina: new imaging technology may spot eye disease earlier
- Stem cell eye transplant aims to halt blindness from rare genetic disease
- Could stem cells restore sight in damaged eyes?
- Gene therapy injection aims to restore sight in rare blindness
- Ground-Level vision test could help retinitis pigmentosa patients walk better